Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

The Effect of BRCA Mutation and Metformin Use on Premature Ovarian Aging

FY 2023-24

Summary
Ovarian cancer is the fifth leading cause of cancer-related mortality for women in Canada and has a 5-year survival rate of 44%. A major risk factor for ovarian cancer is the number of lifetime ovulations; a risk factor which can only be mitigated with oral contraceptives or pregnancy. Effective screening for the early detection of ovarian cancer unfortunately does not exist, and treatment options are limited for cancers which have progressed to a more advanced stage. Women who have hereditary Breast Cancer Gene (BRCA) mutations are at a higher risk of developing breast and ovarian cancer, and currently risk reduction among women with these mutations involves the use of oral contraceptives or surgical removal of both ovaries as well as the fallopian tubes. Our lab has previously found that fibrosis, or the deposition of collagen in the outer portion of the ovary, is increased with age and post-menopausal status. Pre-menopausal women have less fibrosis while post-menopausal women have more fibrosis. We have also noted that BRCA mutations tend to accelerate the presence of ovarian fibrosis. In contrast, we have shown that metformin, a drug commonly used in diabetes patients, can prevent fibrosis in the ovaries of mice. In the general population, metformin use in diabetic women has also been linked to a decreased incidence of ovarian cancer. This study aims to determine the contribution of fibrosis to the recruitment of cancer cells to the ovary, how fibrosis is accelerated or changed in women with hereditary mutations, and to investigate metformin as a possible treatment strategy to prevent fibrosis from occurring. The results from this study will be instrumental in our understanding of the role fibrosis plays in the development of ovarian cancer and will also answer whether metformin could be used for ovarian cancer prevention in high-risk women.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
497345
Name
Murray Alyssa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Effect of BRCA Mutation and Metformin Use on Premature Ovarian Aging
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Age; Brca Mutation; Chemoprevention; Fibroblast Hyperactivity; Fibrosis; Inflammation; Metformin; Ovarian Cancer Risk; Ovary; Transcriptomics
Abstract
Ovarian cancer is the fifth leading cause of cancer-related mortality for women in Canada and has a 5-year survival rate of 44%. A major risk factor for ovarian cancer is the number of lifetime ovulations; a risk factor which can only be mitigated with oral contraceptives or pregnancy. Effective screening for the early detection of ovarian cancer unfortunately does not exist, and treatment options are limited for cancers which have progressed to a more advanced stage. Women who have hereditary Breast Cancer Gene (BRCA) mutations are at a higher risk of developing breast and ovarian cancer, and currently risk reduction among women with these mutations involves the use of oral contraceptives or surgical removal of both ovaries as well as the fallopian tubes. Our lab has previously found that fibrosis, or the deposition of collagen in the outer portion of the ovary, is increased with age and post-menopausal status. Pre-menopausal women have less fibrosis while post-menopausal women have more fibrosis. We have also noted that BRCA mutations tend to accelerate the presence of ovarian fibrosis. In contrast, we have shown that metformin, a drug commonly used in diabetes patients, can prevent fibrosis in the ovaries of mice. In the general population, metformin use in diabetic women has also been linked to a decreased incidence of ovarian cancer. This study aims to determine the contribution of fibrosis to the recruitment of cancer cells to the ovary, how fibrosis is accelerated or changed in women with hereditary mutations, and to investigate metformin as a possible treatment strategy to prevent fibrosis from occurring. The results from this study will be instrumental in our understanding of the role fibrosis plays in the development of ovarian cancer and will also answer whether metformin could be used for ovarian cancer prevention in high-risk women.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Murray, Alyssa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~